Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis

Congratulations to Charles Chiu, Joe DeRisi, Michael Wilson and the Delve Bio team on their $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II and joined by Section 32 and Google Ventures!  UCSF is happy to partner with this talented and experienced team of scientists and investors.    Delve Bio is a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, and its mNGS platform is based on work from the lab of UCSF’s Dr. Charles Chiu.  The company aims to bring the impact genomic testing has had in oncology, women’s health, and rare disease to infectious disease patients who remain underserved and promises to have a wide range of applications in the management of infectious disease in the future, including host response and antimicrobial-resistance monitoring, epidemiologic surveillance and more.  We are very proud of Delve Bio’s progress, especially in the current challenging funding environment.  Thank you to Darya Bubman from Engagement and Opportunity Development Team at UCSF’s Office of Technology Management and Advancement for supporting this technology and partnership.